PARP1 and pancreatic neoplasm: Similarly, Wang et al. have revealed that ALT triggers synergistic lethality with simultaneous PARP-1 inhibition in homologous recombination-proficient cancer cells (Wang et al., 2020), and promotes the therapeutic sensitivity of pancreatic cancer cells to the anti-cancer drugs, including oxaliplatin (He et al., 2018), PARP inhibitor (olaparib) (Wang et al., 2020), epidermal growth factor receptor (EGFR) inhibitors (erlotinib and afatinib) (Zheng et al., 2019), and so on.